NVO is expanding into rare blood disorders like hemophilia to ease reliance on GLP-1 drugs Ozempic and Wegovy.

Catalyst Biosciences is a step closer to challenging Novo Nordisk’s NovoSeven in the haemophilia A and B market.

NovoSeven RT (coagulation factor VIIa, recombinant) is a prescription drug that’s prescribed for hemophilia and certain other bleeding disorders. The drug comes as a powder in a single-dose vial ...

NovoSeven RT is a prescription drug that treats and helps prevent bleeding episodes. Learn about its possible interactions with other drugs, alcohol, and more.

NovoSeven RT is a brand-name drug used to treat hemophilia. Discover drug interactions in depth, warnings and precautions, and more.

NovoSeven RT is a prescription drug used to treat certain blood clotting disorders. Learn about its dosage, side effects, uses, and more.

TU7710, an investigational recombinant factor VIIa, showed an extended half-life compared with NovoSeven, a conventional hemophilia treatment.

Consumer Medicine Information (CMI) about NovoSeven RT (eptacog alfa Recombinant coagulation factor VIIa) intended for persons living in Australia.

Catalyst Biosciences is a step closer to challenging Novo Nordisk’s NovoSeven in the haemophilia A and B market after reporting positive results in a phase 2 trial.

The 300 mcg/vial dosage of WinRho SDF is currently unavailable and the 8 mg of vial of NovoSeven RT is in shortly supply.